---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-014768"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-04-15T23:59:59+00:00"
generated_at: "2026-06-26T07:14:19.201012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brooklyn ImmunoTherapeutics reports FY2021 net loss of $122.3M; cash $17M

## Summary
- Net loss $122.3M for FY2021 vs $26.5M in 2020; Q4 loss $8.5M vs $21.5M.
- Operating expenses $113.6M, including $80.5M acquired IPR&D from Novellus deal.
- Cash $17.0M at Dec 31, 2021, up from $1.6M a year ago; raised $52M via equity sales.
- Completed Novellus acquisition in July 2021; new executives appointed.
- Phase 2b head & neck cancer trial readout for IRX-2 expected Q2 2022.

## SEC filing metadata
- accession: 0001140361-22-014768
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/0001140361-22-014768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/brhc10036443_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-014768
- JSON: https://secwatch.observer/filing/0001140361-22-014768.json
- Plain text: https://secwatch.observer/filing/0001140361-22-014768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.